financetom
Business
financetom
/
Business
/
HBT Financial Q2 adjusted EPS edges past estimates, net income up
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HBT Financial Q2 adjusted EPS edges past estimates, net income up
Jul 21, 2025 4:38 AM

Overview

* HBT Financial ( HBT ) Q2 adjusted EPS of $0.63 beats analyst expectations

* Adjusted net income of $19.8 mln surpasses estimates

* Net interest margin rose to 4.14% due to improved yields and lower costs

Outlook

* HBT Financial, the holding company for Heartland Bank and Trust Co, expects loan growth to return in Q3 2025

* HBT Financial ( HBT ) prepared for varied economic and interest rate environments

* Company's capital levels support acquisition opportunities

* HBT Financial sees fewer loan payoffs projected in Q3 2025

Result Drivers

* NET INTEREST MARGIN - Increased to 4.14% due to improved yields on debt securities and lower funding costs

* LOAN PAYDOWNS - Seasonal paydowns and property sales led to a decrease in loan balances, expected to recover in Q3

* ASSET QUALITY - Maintained strong asset quality with nonperforming assets at 0.13% of total assets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $0.63 $0.6 (5

Adjusted Analysts

EPS )

Q2 EPS $0.61

Q2 Beat $19.80 $19 mln

Adjusted mln (5

Net Analysts

Income )

Q2 Net $19.23

Income mln

Q2 Net $49.66

Interest mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy"

* Wall Street's median 12-month price target for HBT Financial Inc ( HBT ) is $26.00, about 2.7% above its July 18 closing price of $25.31

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Decliners
Top Premarket Decliners
Dec 12, 2024
07:51 AM EST, 12/12/2024 (MT Newswires) -- Keros Therapeutics ( KROS ) shares were down 72% pre-bell Thursday after the company said it voluntarily halted two treatment arms in a phase 2 study of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension. Samfine Creation ( SFHG ) stock was 36% lower, extending Wednesday's fall. Intellinetics (...
Almaden Updated on Arbitration Process with Mexico
Almaden Updated on Arbitration Process with Mexico
Dec 12, 2024
07:48 AM EST, 12/12/2024 (MT Newswires) -- Almaden Minerals Ltd. ( AAUAF ) , trading near 52 week lows, on Thursday provided an update on its international arbitration proceedings under the Comprehensive and Progressive Agreement for Trans-Pacific Partnership with the United Mexican States. While Almaden in a statement said it is vigorously pursuing this claim, its preference is for a...
Volkswagen's board leans against closing big plants in Germany, media report says
Volkswagen's board leans against closing big plants in Germany, media report says
Dec 12, 2024
(Reuters) - Volkswagen's supervisory board is leaning against closing large plants in Germany to tackle the carmaker's cost crisis, a report by business monthly manager magazin said on Thursday, though no final agreement has been reached. Board members discussed stopping production at the 300-person Dresden plant and selling the plant in Osnabrueck which employs around 2,300 people, the German magazine...
Bausch Health Says Bausch + Lomb Subsidiary Sale Under Consideration
Bausch Health Says Bausch + Lomb Subsidiary Sale Under Consideration
Dec 12, 2024
07:50 AM EST, 12/12/2024 (MT Newswires) -- Bausch Health ( BHC ) said Thursday that it has authorized its Bausch + Lomb ( BLCO ) subsidiary to explore a potential sale, among the options under consideration to complete a previously announced plan to separate the two companies. The company believes that completing the full separation of its subsidiary, Bausch +...
Copyright 2023-2026 - www.financetom.com All Rights Reserved